The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


EVUSHELD



AstraZeneca ABEU/1/22/1651/001

Main Information

Trade NameEVUSHELD
Active SubstancesTixagevimab
Cilgavimab
Dosage FormSolution for injection
Licence HolderAstraZeneca AB
Licence NumberEU/1/22/1651/001

Group Information

ATC CodeJ06B IMMUNOGLOBULINS
J06BD03 tixagevimab and cilgavimab

Status

License statusAuthorised
Licence Issued25/03/2022
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back